Clinical Trial Update: An Extension Study of 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids [Phase 2]

View source ↗

Summary

Phase 2 extension study of 12 mg Proellex (telapristone acetate) in premenopausal women with symptomatic uterine fibroids; study terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uterine Fibroids

Drugs mentioned

• Proellex (telapristone acetate)

Snippet

Sponsor: Repros Therapeutics Inc. | Conditions: Uterine Fibroids | Phase 2 | Status: TERMINATED | Results posted: 2019-06-19